---
canonical_name: Magnesium
alternate_names: Mg, Magnesium Glycinate, Magnesium Bisglycinate, Magnesium Citrate, Magnesium Oxide, Magnesium L-Threonate, Magtein, Magnesium Chloride, Magnesium Taurate, Magnesium Malate, Magnesium Sulfate, Epsom Salt, Magnesium Hydroxide, Milk of Magnesia, Magnesium Lactate, Magnesium Orotate, Magnesium Carbonate, Magnesium Gluconate, Magnesium Aspartate
canonical_topic: Magnesium for Health & Longevity
short_topic_lc: magnesium
creation_date: 2026-0822-1251
creator_ai_fullname: Grok 4
ep_keywords: Macrominerals, Electrolytes, Essential Minerals, Minerals
---

# Magnesium for Health & Longevity
<section id="top" markdown="1"></section>
Evidence Review created on 08/22/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Grok 4  

**Also known as:** Mg, Magnesium Glycinate, Magnesium Bisglycinate, Magnesium Citrate, Magnesium Oxide, Magnesium L-Threonate, Magtein, Magnesium Chloride, Magnesium Taurate, Magnesium Malate, Magnesium Sulfate, Epsom Salt, Magnesium Hydroxide, Milk of Magnesia, Magnesium Lactate, Magnesium Orotate, Magnesium Carbonate, Magnesium Gluconate, Magnesium Aspartate  
  

## Motivation
<!-- Motivation written last, after all other sections were completed, so this introduction reflects the full scope of the topic. -->
Magnesium is an essential mineral the body uses as a helper in hundreds of chemical reactions, including energy production, nerve signaling, muscle contraction, and repair of genetic material. It is found in leafy greens, nuts, seeds, legumes, and whole grains. Many diets still fall short of typical intake targets, and oral supplements in several salt forms are widely used to close that gap.  

Interest in magnesium as a longevity tool comes from its roles in blood pressure, blood-sugar handling, and sleep. Epsom salt and milk of magnesia have a long household history as laxatives, and modern use centers on inexpensive over-the-counter oral salts taken as a daily nutrient to close a common intake gap.  

This review examines the human evidence for oral magnesium as a health and longevity intervention. It covers proposed mechanisms, expected benefits and risks, factors that change those outcomes, protocols used in longevity-oriented practice, sourcing, and how response is monitored.  

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**  
  

## Recommended Reading
<!-- Recommended Reading search, 2026-08-22: Web search plus on-site retrieval for "magnesium" on foundmyfitness.com, peterattiamd.com, hubermanlab.com, chriskresser.com, lifeextension.com, and lifespan.io. Dedicated overviews: FoundMyFitness episode #87 (Patrick), Peter Attia AMA #54, Chris Kresser 2022 article, Life Extension Magazine April 2025 (Faloon), Lifespan.io topic page (Hill, 2024). Huberman Lab discusses magnesium mainly as one item in a sleep toolkit (Toolkit for Sleep; Master Your Sleep) without a dedicated magnesium review, so it is noted rather than listed. Excluded Grokipedia, Examine, ConsumerLab, systematic reviews, Wikipedia, forums, and product catalog pages. -->
High-level expert overviews of oral magnesium, forms, deficiency, and longevity-relevant uses.  

- [The Science of Magnesium and Its Role in Aging and Disease](https://www.foundmyfitness.com/episodes/magnesium) - Rhonda Patrick  

A solo episode covering intake gaps, DNA repair, blood pressure, sleep, cognition, and how serum tests can miss low tissue stores.  

- [#282 – AMA #54: Magnesium: risks of deficiency, how to correct it, supplement options, potential cognitive and sleep benefits, and more](https://peterattiamd.com/ama54/) - Peter Attia  

A clinician-level walk through deficiency harms, testing limits, salt forms, and Attia's own mixed-form intake approach.  

- [Magnesium: An essential nutrient that most people don’t get enough of](https://chriskresser.com/magnesium-an-essential-nutrient-that-most-people-dont-get-enough-of/) - Chris Kresser  

A practical overview of enzymatic roles, why typical diets undershoot needs, and why amino-acid-bound (chelated) salts are preferred over poorly absorbed oxide.  

- [As We See It: Magnesium Disorders](https://www.lifeextension.com/magazine/2025/4/magnesium-disorders) - William Faloon  

A magazine commentary on a 2024 *New England Journal of Medicine* review, restating how slowly clinical practice treated magnesium as more than a forgotten electrolyte.  

- [Magnesium: Benefits and Side Effects](https://lifespan.io/topic/magnesium-benefits-side-effects/) - Steve Hill  

A longevity-site summary of enzymatic roles, cardiovascular associations, supplementation, and remaining uncertainty on hard outcomes.  

Andrew Huberman discusses magnesium mainly as a sleep-toolkit component rather than in a dedicated magnesium review, so no Huberman item is listed.  
  

## Grokipedia
<!-- Grokipedia search, 2026-08-22: browser_navigate to https://grokipedia.com/search?q=magnesium. Hits included /page/Magnesium (element) and /page/Magnesium_supplements (intervention). Used the dedicated supplements page. -->

- [Magnesium supplements](https://grokipedia.com/page/Magnesium_supplements)  

A single-page overview of oral salt forms, absorption differences, and clinical uses that sits between a chemistry article and a dosing guide.  
  

## Examine
<!-- Examine.com search, 2026-08-22: retrieved https://examine.com/supplements/magnesium/ (H1 Magnesium; last updated 2026-08-10). Dedicated supplement page exists. d-browser hit a Vercel checkpoint; page recovered via d-proxy-2. -->

- [Magnesium](https://examine.com/supplements/magnesium/)  

Evidence grades across blood pressure, glucose, sleep, constipation, and migraine, plus form-specific bioavailability and a safety/interaction database.  
  

## ConsumerLab
<!-- ConsumerLab search, 2026-08-22: retrieved https://www.consumerlab.com/reviews/magnesium-supplement-review/magnesium/ (updated 2026-06-25). Dedicated product review exists. -->

- [Magnesium Supplements Review (Including Calcium, Vitamins D & K, and Boron)](https://www.consumerlab.com/reviews/magnesium-supplement-review/magnesium/)  

Independent tests of labeled elemental content, salt-form accuracy, and contaminants, with notes on which forms absorb well versus act mainly as laxatives.  
  

## Systematic Reviews
Meta-analyses of oral magnesium for blood pressure, glucose, mortality associations, sleep, and the commonly claimed use for muscle cramps.  

- [Magnesium Supplementation and Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials](https://pubmed.ncbi.nlm.nih.gov/41000008/) - Argeros et al., 2025  

Thirty-eight trials; systolic/diastolic pressure fell overall, with larger drops in treated hypertension and low baseline magnesium.  

- [Oral Magnesium Supplementation for Treating Glucose Metabolism Parameters in People with or at Risk of Diabetes: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials](https://pubmed.ncbi.nlm.nih.gov/34836329/) - Veronese et al., 2021  

Twenty-five placebo-controlled trials: fasting glucose improved in diabetes; insulin-resistance markers improved in high-risk groups.  

- [Total, Dietary, and Supplemental Magnesium Intakes and Risk of All-Cause, Cardiovascular, and Cancer Mortality: A Systematic Review and Dose-Response Meta-Analysis of Prospective Cohort Studies](https://pubmed.ncbi.nlm.nih.gov/33684200/) - Bagheri et al., 2021  

Dietary magnesium associated with lower all-cause and cancer death; supplemental magnesium was not.  

- [Magnesium for skeletal muscle cramps](https://pubmed.ncbi.nlm.nih.gov/32956536/) - Garrison et al., 2020  

Cochrane review: oral magnesium is unlikely to prevent idiopathic (of unknown cause) cramps in older adults; gastrointestinal adverse events were more common.  

- [Oral magnesium supplementation for insomnia in older adults: a Systematic Review & Meta-Analysis](https://pubmed.ncbi.nlm.nih.gov/33865376/) - Mah & Pitre, 2021  

Pooled sleep-onset was shorter, but evidence certainty was low to very low and trials were small.  
  

## Mechanism of Action
Magnesium is the second most abundant ion inside cells. It stabilizes adenosine triphosphate (ATP, the cell's energy currency) so hundreds of enzymes can run energy metabolism, protein synthesis, and DNA repair. In neurons it occupies the channel of N-methyl-D-aspartate (NMDA, a brain receptor that magnesium can block) receptors, limiting excitatory calcium entry. In blood-vessel muscle it behaves as a physiologic calcium antagonist, favoring relaxation. In muscle and pancreas it supports insulin-receptor signaling.  

Uptake in the gut uses both between-cell (paracellular) flow and transient receptor potential melastatin 6 and 7 (TRPM6/TRPM7, intestinal magnesium channels). The kidney reabsorbs most filtered magnesium; when estimated glomerular filtration rate (eGFR, a kidney-function estimate) falls, magnesium can accumulate. About 50–60% of body magnesium sits in bone, about 1% in serum, and the rest in cells. Oral salts are not broken down by liver cytochrome enzymes; unabsorbed magnesium stays in the bowel (the osmotic laxative effect) and absorbed magnesium leaves in urine. After an intravenous load, serum half-life is on the order of a few hours with normal kidneys; whole-body stores turn over over weeks because of the bone pool. Organic salts (citrate, glycinate, chloride) generally raise circulating and urine magnesium more than oxide. A competing view holds that serum magnesium is a poor tissue marker, so repletion can occur without a large serum change, and that some health associations reflect overall diet quality rather than magnesium itself.  
  

## Historical Context & Evolution
Epsom salt (magnesium sulfate) was used as a purgative from the seventeenth century. Humphry Davy isolated elemental magnesium in 1808. Magnesium hydroxide (“milk of magnesia”) became a household antacid and laxative. In obstetrics, intravenous magnesium sulfate became standard for eclamptic seizures (seizures from pregnancy-related high blood pressure) in the twentieth century—a different route, dose, and purpose from oral supplementation.  

From the 1980s, reviews called magnesium a “forgotten electrolyte” and “nature’s calcium blocker.” National diet surveys then showed that a large share of adults missed recommended dietary allowances. Randomized trials of oral magnesium for blood pressure, glucose, migraine, and sleep accumulated from the 1990s, with uneven quality and mixed results. Magnesium L-Threonate was developed in the 2010s as a form intended to raise brain magnesium; early human trials were small and industry-linked. A 2024 *New England Journal of Medicine* review on magnesium disorders ([Touyz et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38838313/)), discussed in Life Extension’s coverage, restated how slowly ordinary care treated magnesium as more than a laboratory afterthought. Opinion moved from “overt deficiency is rare” toward “inadequacy is common,” without showing that routine high-dose supplementation extends lifespan. Dietary-cohort associations remain stronger than supplement trials for death and major cardiovascular events.  
  

## Expected Benefits
<!-- Benefit-profile search, 2026-08-22: PubMed systematic reviews/meta-analyses and RCTs for oral magnesium on blood pressure, glucose, inflammation, migraine, sleep, constipation, bone, depression/anxiety, premenstrual symptoms, cramps, restless legs, cognition, and mortality; plus Examine, ConsumerLab, NIH-style drug/supplement references. -->

### High 🟩 🟩 🟩

#### Modest Blood Pressure Reduction

Pooled randomized trials show a small average drop in clinic blood pressure with oral magnesium, larger in people already on blood-pressure medication or with low magnesium at baseline, and smaller or absent in people with already-normal pressure. Proposed mechanisms are vascular smooth-muscle relaxation and mild calcium antagonism. Two independent meta-analyses of randomized, mostly double-blind trials (2016 and 2025) reach the same direction with high heterogeneity.  

**Magnitude:** Median ~365–368 mg/day elemental magnesium for ~12 weeks lowered systolic pressure by 2.00–2.81 mm Hg and diastolic pressure by 1.78–2.05 mm Hg versus placebo (95% confidence interval, CI, the range likely to contain the true value, for the 2016 systolic estimate 0.43–3.58); treated hypertension showed ~7.7 mm Hg systolic in the 2025 pooling ([Zhang et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27402922/); [Argeros et al., 2025](https://pubmed.ncbi.nlm.nih.gov/41000008/)).  

#### Relief of Functional Constipation

Poorly absorbed salts, especially oxide and citrate, hold water in the bowel and act as osmotic laxatives. That is a documented therapeutic use, not only an adverse event. A randomized trial of magnesium oxide and a systematic review of over-the-counter constipation therapies both support this effect in chronic constipation.  

**Magnitude:** Magnesium oxide 1.5 g/day produced overall constipation improvement in 68.3% versus 11.7% on placebo, with a larger rise in complete spontaneous bowel movements ([Morishita et al., 2021](https://pubmed.ncbi.nlm.nih.gov/32969946/); [Rao & Brenner, 2021](https://pubmed.ncbi.nlm.nih.gov/33767108/)).  

### Medium 🟩 🟩

#### Improved Glucose Handling

In people with type 2 diabetes or high diabetes risk, oral magnesium improved fasting glucose and insulin-resistance scores in a meta-analysis of 25 double-blind randomized trials (median 12–14 weeks). Magnesium supports insulin-receptor signaling; effects were larger when serum magnesium rose. Trials were small and used mixed salts, often oxide.  

**Magnitude:** Fasting glucose standardized mean difference (how large the change is relative to typical variation) −0.43 versus placebo in diabetes (11 trials); in high-risk groups fasting glucose standardized mean difference was −0.34 and homeostatic model assessment of insulin resistance (HOMA-IR, a calculated insulin-resistance score) standardized mean difference was −0.23 ([Veronese et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34836329/)).  

#### Lower Circulating C-Reactive Protein

A meta-analysis of 17 randomized trials (889 participants) found oral magnesium lowered serum C-reactive protein (CRP, a blood marker of inflammation) and raised nitric oxide, consistent with less vascular inflammatory signaling. Most cohorts had metabolic conditions. Heterogeneity was high, so this is an anti-inflammatory signal rather than a proven event-rate reduction.  

**Magnitude:** CRP standardized mean difference −0.36 (95% CI −0.66 to −0.05) versus placebo across 15 analyzable trials ([Veronese et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35277037/)).  

#### Migraine Frequency Reduction ⚠️ Conflicted

Oral magnesium is a longstanding migraine-prevention option, possibly via NMDA blockade and vessel-muscle relaxation. One meta-analysis of randomized trials reported lower attack frequency and intensity; a systematic review judged the rationale only moderately evidence-based at about 600 mg/day. Trial quality is uneven, and intravenous emergency-department use is a separate intervention.  

**Magnitude:** Oral magnesium reduced migraine frequency (odds ratio, OR, the odds of the outcome on treatment versus control, 0.20) and intensity (OR 0.27) in a 10-trial pooling of 789 participants; evidence quality is mixed ([Chiu et al., 2016](https://pubmed.ncbi.nlm.nih.gov/26752497/); [von Luckner & Riederer, 2018](https://pubmed.ncbi.nlm.nih.gov/29131326/)).  

### Low 🟩

#### Sleep Quality ⚠️ Conflicted

Magnesium can block excitatory NMDA channels. Observational work links higher status to better sleep, and a small older-adult meta-analysis found faster onset. A broader review found randomized results uncertain. GRADE (a system for rating how certain the evidence is) rated the pooling low to very low certainty.  

**Magnitude:** Sleep-onset latency was 17 minutes shorter versus placebo in three small trials of older adults; total sleep time was not clearly longer ([Mah & Pitre, 2021](https://pubmed.ncbi.nlm.nih.gov/33865376/); [Arab et al., 2023](https://pubmed.ncbi.nlm.nih.gov/35184264/)).  

#### Depressive and Anxiety Symptoms

Magnesium may calm excitatory NMDA signaling. An open-label randomized crossover of magnesium chloride (248 mg elemental/day) improved depression and anxiety scores within two weeks, but there was no placebo. A systematic review of anxiety trials called the evidence suggestive and poor-quality.  

**Magnitude:** Patient Health Questionnaire-9 (PHQ-9, a depression symptom score) improved by 6.0 points versus no treatment in one open-label trial ([Tarleton et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28654669/); [Boyle et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28445426/)).  

#### Premenstrual Symptom Relief

Small randomized trials report premenstrual mood relief, possibly via prostaglandin and nerve-signaling effects. In one 32-woman double-blind trial, 360 mg improved total and negative-affect scores versus placebo. Samples are small, and a later observational meta-analysis found no consistent serum-magnesium difference ([Moslehi et al., 2019](https://pubmed.ncbi.nlm.nih.gov/30880352/)).  

**Magnitude:** Premenstrual total and negative-affect scores improved versus placebo in a 32-woman trial of 360 mg magnesium; the literature reports no pooled outcome figure ([Facchinetti et al., 1991](https://pubmed.ncbi.nlm.nih.gov/2067759/)).  

#### Hip Bone Mineral Density

Higher magnesium intake tracks with slightly higher hip bone mineral density in older adults, consistent with magnesium as a bone-mineral constituent that supports parathyroid and vitamin D handling of calcium. Almost all data are observational; large, long supplementation trials on fractures are missing.  

**Magnitude:** Pooled observational beta (a regression slope relating intake to bone density) for hip bone mineral density 0.03 (95% CI 0.01–0.06); fracture effects were not established ([Groenendijk et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34666201/)).  

#### Idiopathic Muscle Cramps ⚠️ Conflicted

Cramps are a common reason people take magnesium, given its role in muscle relaxation. In older adults with idiopathic rest cramps, Cochrane found no meaningful prevention. Pregnancy-associated cramp trials conflict. Gastrointestinal adverse events were more common on magnesium.  

**Magnitude:** Difference versus placebo −0.18 cramps/week at four weeks (95% CI −0.84 to 0.49); not clinically meaningful ([Garrison et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32956536/)).  

#### Restless Legs Symptoms ⚠️ Conflicted

Restless legs are a common reason people take magnesium, given its neuromuscular effects. A 2019 systematic review could not conclude that supplements work; the one randomized trial was negative and possibly underpowered. A later mixed-supplement review reported symptom improvement with magnesium oxide. Evidence remains thin and conflicted.  

**Magnitude:** The one randomized trial in the 2019 pooling did not find a significant treatment effect; the literature reports no pooled outcome figure ([Marshall et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31678660/); [González-Parejo et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39064758/)).  

#### Lower Post-Exercise Muscle Soreness

A four-trial systematic review in physically active people found oral magnesium reduced delayed-onset muscle soreness and some muscle-damage markers, possibly by limiting contraction-related damage signaling. Doses and salts varied, samples were small, and results were not pooled.  

**Magnitude:** Trials reported less post-exercise soreness versus control; the literature reports no pooled outcome figure ([Tarsitano et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38970118/)).  

### Speculative 🟨

#### Cognitive Performance with Magnesium L-Threonate

L-Threonate is designed to raise brain magnesium across the blood-brain barrier. A small industry-linked trial reported cognitive gains in older adults; replication is limited ([Liu et al., 2016](https://pubmed.ncbi.nlm.nih.gov/26519439/); [Chen et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39009081/)).  

#### Lower Death Rates from Food, Not Supplements

Cohorts link higher dietary magnesium with lower death rates; supplemental magnesium was not. A longevity benefit from oral supplements remains unshown ([Fang et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27927203/); [Bagheri et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33684200/)).  
  

## Benefit-Modifying Factors

- **Baseline magnesium:** Blood-pressure and glucose effects are larger when serum magnesium is low and when circulating magnesium actually rises on treatment ([Argeros et al., 2025](https://pubmed.ncbi.nlm.nih.gov/41000008/); [Veronese et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34836329/)).  
- **Kidney function:** Intact kidneys both enable repletion and protect against accumulation; falling eGFR blunts urinary wasting but raises toxicity risk before extra benefit appears ([de Baaij et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25540137/)).  
- **Salt form:** Citrate, glycinate, chloride, and lactate raise body stores more than oxide; oxide and citrate remain more useful when the goal is laxation ([Pardo et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34111673/)).  
- **Sex:** Women have a lower recommended dietary allowance (310–320 versus 400–420 mg/day). Premenstrual symptom trials exist but are small; pregnancy uses a separate intravenous protocol not reviewed here ([Boyle et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28445426/)).  
- **Age:** Older adults eat less magnesium, absorb less, and use more acid-suppressing drugs, so repletion benefit is more plausible and excess risk is higher ([Rosanoff et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22364157/)).  
- **Metabolic disease:** Type 2 diabetes, insulin resistance, and treated hypertension are the groups in which trial benefits concentrate ([Veronese et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34836329/); [Argeros et al., 2025](https://pubmed.ncbi.nlm.nih.gov/41000008/)).  
- **Vitamin D status:** In a Vanderbilt randomized trial, magnesium raised vitamin D when it was low and lowered it when it was high, acting as a thermostat rather than a simple booster ([Dai et al., 2018](https://pubmed.ncbi.nlm.nih.gov/30541089/)).  
- **Genetics:** Rare variants in TRPM6, cyclin M2 (CNNM2, a magnesium-transport gene), and related channels cause hereditary hypomagnesemia (genetically low blood magnesium); no common panel currently retitrates ordinary oral doses ([de Baaij et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25540137/)).  
  

## Potential Risks & Side Effects
<!-- Risk-profile search, 2026-08-22: PubMed (hypermagnesemia, diarrhea, constipation, adverse events), Gröber drug-interaction review, Hess PPI hypomagnesemia SR, Garrison Cochrane AE pooling, Examine safety summary, ConsumerLab cautions, MAGiCAL-CKD SAE signal. -->

### High 🟥 🟥 🟥

#### Gastrointestinal Upset and Diarrhea

Unabsorbed magnesium pulls water into the bowel. Diarrhea, nausea, and cramping are the dose-limiting effects in people with normal kidneys and the basis for the 350 mg/day supplemental tolerable upper intake level. Oxide and high-dose citrate provoke this more than glycinate. Cochrane cramp trials reported minor gastrointestinal events in 11–37% of magnesium arms versus 10–14% on placebo.  

**Magnitude:** Relative risk (how many times more often the event occurs on magnesium than on placebo) of minor adverse events 1.51 (95% CI 0.98–2.33) versus placebo in four cramp trials; diarrhea is the usual limiter below toxic serum levels ([Garrison et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32956536/); [Gröber, 2019](https://pubmed.ncbi.nlm.nih.gov/31035385/)).  

#### Hypermagnesemia When Kidneys Cannot Excrete the Load

High blood magnesium (hypermagnesemia, excess magnesium in blood) can cause low blood pressure, slowed heart conduction, muscle weakness, and, at extreme levels, respiratory failure. With healthy kidneys this is uncommon at ordinary supplemental doses. Risk rises with eGFR below about 30 mL/min/1.73 m², high-dose laxatives or antacids, and bowel stasis. MAGiCAL-CKD reported more gastrointestinal events and a numerical excess of deaths and cardiovascular events on magnesium hydroxide in advanced chronic kidney disease.  

**Magnitude:** Toxicity is rare with eGFR >60 mL/min at ≤350 mg supplemental elemental magnesium/day and concentrates in reduced kidney function and gram-level laxative or antacid use; the literature reports no incidence figure at ordinary repletion doses in people with healthy kidneys ([Van Laecke, 2019](https://pubmed.ncbi.nlm.nih.gov/30220246/); [Bressendorff et al., 2023](https://pubmed.ncbi.nlm.nih.gov/36749131/)).  

### Medium 🟥 🟥

#### Impaired Absorption of Other Oral Drugs

Magnesium binds some drugs in the gut and can raise gastric pH, lowering absorption of bisphosphonates (bone-density drugs), tetracyclines (antibiotics), fluoroquinolones (another antibiotic class), and levothyroxine. This is a pharmacokinetic interaction, not a magnesium-toxicity event. Spacing doses restores most of the effect.  

**Magnitude:** Clinically important absorption loss occurs when magnesium is co-ingested; the literature reports no single outcome figure. Separation of 2–6 hours is the usual mitigation ([Gröber, 2019](https://pubmed.ncbi.nlm.nih.gov/31035385/)).  

#### Additive Blood-Pressure Lowering

The same vasodilating action that is a benefit can add to antihypertensive drugs, especially calcium-channel blockers (blood-pressure drugs that relax vessel muscle) and other vasodilators. Symptomatic low blood pressure is uncommon at repletion doses and more plausible at high serum levels.  

**Magnitude:** Trial blood-pressure drops of ~2–3 mm Hg average, larger in treated hypertension, imply additive hypotensive potential rather than frequent collapse ([Argeros et al., 2025](https://pubmed.ncbi.nlm.nih.gov/41000008/)).  

### Low 🟥

#### Secondary Electrolyte Shifts

Severe high magnesium can lower calcium and disturb potassium. Isolated oral repletion in healthy kidneys rarely does this; it appears mainly with toxicity, proton-pump inhibitor (PPI, acid-reducing medication)–related wasting, or diuretic combinations.  

**Magnitude:** Not quantified in available studies. Isolated oral repletion in healthy kidneys rarely produces these shifts; reports are case series in marked hypermagnesemia or combined wasting ([Van Laecke, 2019](https://pubmed.ncbi.nlm.nih.gov/30220246/); [Hess et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22762246/)).  

### Speculative 🟨

#### High Serum Magnesium and Cognition

A 2024 review found both low and high serum magnesium linked to dementia, with a nadir near 0.85 mmol/L. That is observational, not a proven supplement harm ([Chen et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39009081/)).  
  

## Risk-Modifying Factors

- **Kidney function:** eGFR below ~30 mL/min/1.73 m² is the dominant risk amplifier for hypermagnesemia and was the setting of excess serious events in MAGiCAL-CKD ([Bressendorff et al., 2023](https://pubmed.ncbi.nlm.nih.gov/36749131/)).  
- **Baseline serum magnesium:** Higher starting levels mean smaller circulating rises and more urinary spill, but less room before the toxic range ([Zhang et al., 2016](https://pubmed.ncbi.nlm.nih.gov/26865651/)).  
- **Sex:** No consistent excess of serious toxicity in women at repletion doses; pregnancy intravenous protocols are a separate high-dose medical use ([de Baaij et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25540137/)).  
- **Age:** Older adults combine lower eGFR, more PPI and diuretic use, and more constipation-driven high-dose oxide, raising both gut and systemic risk ([Rosanoff et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22364157/)).  
- **Gastrointestinal disease:** Inflammatory bowel disease, slow transit, or obstruction can increase absorption or, rarely, an oxide bezoar (a trapped gut mass); diarrhea-predominant states increase wasting ([Examine safety summary](https://examine.com/supplements/magnesium/)).  
- **Drug-induced wasting:** PPIs, loop and thiazide diuretics (water-loss drugs), and calcineurin inhibitors (transplant anti-rejection drugs) lower magnesium; repletion may be needed, but the drugs remain a risk context ([Hess et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22762246/); [Gröber, 2019](https://pubmed.ncbi.nlm.nih.gov/31035385/)).  
- **Genetics:** Loss-of-function TRPM6 or CNNM2 variants impair conservation; they raise deficiency risk more than supplement toxicity ([de Baaij et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25540137/)).  
  

## Key Interactions & Contraindications

- **Bisphosphonates (alendronate, risedronate):** Caution — magnesium chelates and cuts absorption; separate by at least 2 hours, preferably magnesium later in the day ([Gröber, 2019](https://pubmed.ncbi.nlm.nih.gov/31035385/)).  
- **Tetracyclines (doxycycline) and fluoroquinolones (ciprofloxacin):** Caution — chelation lowers antibiotic levels; take magnesium 2 hours before or 4–6 hours after ([Gröber, 2019](https://pubmed.ncbi.nlm.nih.gov/31035385/)).  
- **Levothyroxine:** Caution — reduced thyroid-hormone absorption; separate by 4 hours.  
- **Gabapentin:** Caution — magnesium can lower gabapentin absorption; separate by at least 2 hours.  
- **Sotalol:** Caution — magnesium antacids can reduce sotalol absorption; separate doses by 2 hours.  
- **PPIs (omeprazole, esomeprazole, pantoprazole):** Monitor — class effect of urinary/intestinal magnesium loss after months to years; repletion may be used while the PPI is reviewed ([Hess et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22762246/)).  
- **Loop and thiazide diuretics (furosemide, hydrochlorothiazide):** Monitor — renal magnesium wasting; potassium-sparing agents (spironolactone, amiloride) can raise magnesium.  
- **Calcium-channel blockers (amlodipine, verapamil) and other antihypertensives:** Caution — additive blood-pressure lowering; more relevant at high serum magnesium ([Argeros et al., 2025](https://pubmed.ncbi.nlm.nih.gov/41000008/)).  
- **Potassium and other blood-pressure-lowering supplements (CoQ10, coenzyme Q10; garlic):** Caution — additive vasodilating effect with magnesium; combining several hypotensive supplements can drop pressure more than magnesium alone.  
- **Calcium supplements:** Caution — compete for absorption; staggered dosing is common in bone protocols.  
- **Vitamin D:** Monitor — magnesium participates in vitamin D metabolism; the Dai trial found bidirectional effects on 25-hydroxyvitamin D ([Dai et al., 2018](https://pubmed.ncbi.nlm.nih.gov/30541089/)).  
- **High-dose zinc:** Caution — high zinc can impair magnesium (and copper) balance if taken chronically together; stagger doses or avoid long concurrent high-dose zinc.  
- **Magnesium-containing antacids and laxatives (milk of magnesia, magnesium citrate):** Caution — additive osmotic load and hypermagnesemia risk, especially in low eGFR ([Van Laecke, 2019](https://pubmed.ncbi.nlm.nih.gov/30220246/)).  
- **Digoxin:** Monitor — low magnesium increases digoxin arrhythmia risk; this is a deficiency interaction, not an excess one ([Gröber, 2019](https://pubmed.ncbi.nlm.nih.gov/31035385/)).  

**Populations who should avoid Magnesium:**  

- Advanced chronic kidney disease (eGFR <30 mL/min/1.73 m²) unless a clinician is targeting and monitoring serum magnesium.  
- Documented hypermagnesemia.  
- Complete heart block (a severely slowed electrical heart rhythm) without a pacemaker, at high or intravenous doses.  
- Myasthenia gravis (a neuromuscular disease with muscle weakness), especially injected (parenteral) magnesium (blockade risk).  
- Known bowel obstruction (oxide has rare bezoar reports at gram-level doses).  
  

## Risk Mitigation Strategies

- **Start below bowel tolerance:** Protocols typically begin near 100–200 mg elemental magnesium/day and raise every 1–2 weeks to limit diarrhea, the usual dose-limiting event ([Garrison et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32956536/)).  
- **Prefer glycinate if gut-limited:** Chelated glycinate/bisglycinate is used when repletion is the goal and oxide-type loose stools appear ([Pardo et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34111673/)).  
- **Check eGFR first:** Kidney function is confirmed before doses above the 350 mg supplemental upper level to reduce hypermagnesemia risk ([Van Laecke, 2019](https://pubmed.ncbi.nlm.nih.gov/30220246/)).  
- **Split the daily amount:** Two or three smaller doses raise absorption and cut osmotic peaks versus one large evening load ([Zhang et al., 2016](https://pubmed.ncbi.nlm.nih.gov/26865651/)).  
- **Separate from chelatable drugs:** Two hours before or 4–6 hours after bisphosphonates, thyroid hormone, tetracyclines, and quinolones protects those drugs’ absorption ([Gröber, 2019](https://pubmed.ncbi.nlm.nih.gov/31035385/)).  
- **Cap non-laxative intake:** Non-laxative supplemental intake is typically kept near 200–400 mg elemental to limit diarrhea and hypermagnesemia unless a constipation protocol is intended.  
- **Reassess PPIs and diuretics:** Long-term PPIs and loop/thiazide diuretics are common reversible wasting causes; reviewing them reduces ongoing deficiency risk ([Hess et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22762246/)).  
  

## Therapeutic Protocol

- **Common longevity range:** Many longevity clinicians describe 200–400 mg/day elemental magnesium from supplements, on top of food, staying near the 350 mg supplemental upper level unless laxation is intended ([Attia AMA #54](https://peterattiamd.com/ama54/); [Patrick episode #87](https://www.foundmyfitness.com/episodes/magnesium)).  
- **Competing approaches:** Conventional nutrition aims at the recommended dietary allowance from food first. Integrative practice often uses standing chelated supplements. Obstetric intravenous sulfate is a different therapy and is not a longevity protocol.  
- **Who popularized mixed salts:** Peter Attia describes combining more than one salt (often glycinate plus a slower inorganic form). Andrew Huberman popularized evening threonate or bisglycinate as a sleep-toolkit item, not a full repletion protocol.  
- **Time of day:** Evening use is common when sleep is the target; split morning/evening use is common when the target is body stores or blood pressure.  
- **Half-life:** Serum magnesium after a load falls over hours with normal kidneys; tissue and bone pools turn over over weeks, so daily rather than as-needed use is the repletion pattern ([de Baaij et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25540137/)).  
- **Single versus split:** Split doses (for example 100–200 mg elemental two or three times daily) are used to improve absorption and limit diarrhea ([Zhang et al., 2016](https://pubmed.ncbi.nlm.nih.gov/26865651/)).  
- **Genetics:** Rare TRPM6/CNNM2 disease changes conservation; no common pharmacogenetic test currently sets the oral dose ([de Baaij et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25540137/)).  
- **Sex:** Women often use the lower end of the range (total intake target ~310–320 mg/day from all sources); men ~400–420 mg/day.  
- **Age:** Older adults often need more attention to eGFR, PPI use, and oxide-related diarrhea than to a higher milligram target.  
- **Baseline labs:** Low serum or red-cell magnesium, treated hypertension, and insulin resistance are the usual reasons protocols are intensified ([Argeros et al., 2025](https://pubmed.ncbi.nlm.nih.gov/41000008/)).  
- **Pre-existing disease:** Type 2 diabetes and hypertension are the trial-supported use cases; advanced kidney disease is a stop or specialist-only setting ([Veronese et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34836329/)).  
  

## Discontinuation & Cycling

- **Duration:** Oral magnesium is treated as a standing nutrient, not a finite drug course, when the aim is to cover a chronic intake gap.  
- **Withdrawal:** No classic withdrawal syndrome is described; serum and urine magnesium fall toward baseline over days to weeks after stopping ([Zhang et al., 2016](https://pubmed.ncbi.nlm.nih.gov/26865651/)).  
- **Taper:** A formal taper is not required at repletion doses; stopping is immediate if hypermagnesemia, severe diarrhea, or a falling eGFR appears.  
- **Cycling:** Cycling is not used to preserve efficacy. Tolerance of the laxative effect can occur; that is not loss of a pharmacologic receptor effect.  
- **After PPI or diuretic changes:** Dose is often reduced if a wasting drug is stopped and diet already meets the recommended allowance.  
  

## Sourcing and Quality

- **Elemental versus compound weight:** Labels that quote milligrams of magnesium oxide, not elemental magnesium, overstate the dose; oxide is about 60% elemental, glycinate much less.  
- **Third-party testing:** USP (United States Pharmacopeia), NSF (an independent product-testing body), or ConsumerLab-tested lots address wrong salt identity and under-dosed products ([ConsumerLab Magnesium Review](https://www.consumerlab.com/reviews/magnesium-supplement-review/magnesium/)).  
- **Form matched to goal:** Glycinate/bisglycinate for repletion with fewer loose stools; citrate when both repletion and stool softness are wanted; oxide mainly as a laxative ([Pardo et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34111673/)).  
- **Threonate caveats:** Magnesium L-Threonate (Magtein) is patented; milligrams of the salt are not equivalent to elemental magnesium toward the recommended allowance, and cognitive trials are industry-linked ([Liu et al., 2016](https://pubmed.ncbi.nlm.nih.gov/26519439/)).  
- **Reputable makers:** Commonly cited tested lines include Thorne, Pure Encapsulations, Life Extension, and NOW; brand is secondary to elemental dose, salt, and a current test report.  
- **Topical Epsom salt:** Transdermal absorption from baths is not a reliable repletion method in human evidence ([Examine form discussion](https://examine.com/supplements/magnesium/)).  
  

## Practical Considerations

- **Time to effect:** Bowel effects can appear within a day. Sleep or mood changes, when they occur, are often reported within 1–2 weeks. Blood pressure and glucose shifts were measured at 4–12 weeks in trials ([Argeros et al., 2025](https://pubmed.ncbi.nlm.nih.gov/41000008/); [Tarleton et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28654669/)).  
- **Common pitfalls:** Using oxide for sleep or brain goals; counting compound weight as elemental magnesium; combining several magnesium products plus antacids; ignoring eGFR.  
- **Regulatory status:** In the United States, oral magnesium is a dietary supplement under the Dietary Supplement Health and Education Act, except drug-labeled laxatives and antacids and prescription intravenous sulfate.  
- **Cost and access:** Ordinary glycinate or citrate is inexpensive and widely sold. Magnesium L-Threonate is several-fold costlier per milligram of elemental magnesium.  
- **Food still counts:** High-dose oral supplements do not replace leafy greens, nuts, seeds, and legumes as the dietary pattern tied to mortality cohorts ([Bagheri et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33684200/)).  
  

## Interaction with Foundational Habits

- **Sleep:** Direct and often potentiating for sleep onset with evening glycinate or threonate, via NMDA blockade and GABA (the brain's main calming messenger); evidence is mixed. Late oxide diarrhea can fragment sleep. Typical toolkit timing is 30–60 minutes before bed ([Mah & Pitre, 2021](https://pubmed.ncbi.nlm.nih.gov/33865376/)).  
- **Nutrition:** Direct. Refined grains, low vegetable intake, high alcohol, and high phytate (plant compounds that bind minerals) patterns lower magnesium. High calcium loads compete. Vitamin D metabolism is magnesium-dependent ([Dai et al., 2018](https://pubmed.ncbi.nlm.nih.gov/30541089/)).  
- **Exercise:** Indirect/potentiating. Sweat and high energy turnover raise needs; some sports contexts use 10–20% above the recommended allowance. Cramps after training still lack good evidence of prevention ([Garrison et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32956536/)).  
- **Stress management:** Indirect. Stress-hormone (catecholamine) states increase urinary magnesium loss; repletion does not replace behavioral stress tools. Anxiety trial evidence remains poor-quality ([Boyle et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28445426/)).  
  

## Monitoring Protocol & Defining Success
Baseline testing before a standing repletion protocol typically includes serum magnesium, red-blood-cell magnesium, a comprehensive metabolic panel with eGFR, and blood pressure, plus fasting glucose or hemoglobin A1c (a three-month average blood-sugar marker) when metabolic benefit is the aim. High-sensitivity CRP is optional if inflammation is a target. Ongoing monitoring is commonly repeated at 8–12 weeks after a stable dose, then every 6–12 months, with earlier checks if eGFR is reduced or high-dose oxide or citrate is used as a laxative. Serum magnesium is a poor tissue marker; some practitioners treat a stable serum value plus rising red-cell and 24-hour urine magnesium as a repletion signal. Kidney function is the safety gate for dose.  

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
| --- | --- | --- | --- |
| Serum magnesium | 2.0–2.5 mg/dL (≈0.82–1.03 mmol/L) | Screens deficit and toxicity | Conventional 1.7–2.2 mg/dL (0.70–0.90 mmol/L); fasting not required; morning serial draws; ~1% of body stores; cognition nadir near 0.85 mmol/L ([Chen et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39009081/)) |
| Red-blood-cell magnesium | 5.0–6.5 mg/dL | Closer to tissue stores than serum | Conventional ~4.2–6.8 mg/dL; not standardized across labs; used in functional-medicine protocols |
| 24-hour urine magnesium | Rise toward ~3–5 mmol/day on a stable dose | Confirms absorption and intake | Fasting not required; collect a full 24 hours; high urine with low serum suggests wasting |
| eGFR | ≥60 mL/min/1.73 m² before unsupervised high-dose use | Safety gate for accumulation | Repeat at 8–12 weeks if baseline <60; <30 is specialist-only |
| Sitting blood pressure | No established magnesium-specific target; track change from the person's seated baseline (trial-level change is a few mm Hg) | Tracks the strongest clinical signal | Same-arm, seated, duplicate readings; recheck at 8–12 weeks ([Argeros et al., 2025](https://pubmed.ncbi.nlm.nih.gov/41000008/)) |
| Fasting glucose or hemoglobin A1c | Change from the person's baseline; no universal magnesium-specific target | Tracks metabolic response | Fasting glucose; hemoglobin A1c need not be fasting |
| High-sensitivity CRP | <1.0 mg/L as a general functional target | Optional inflammation marker | Conventional often <3.0 mg/L; not magnesium-specific; pooled trials showed a modest CRP fall ([Veronese et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35277037/)) |

Qualitative markers:  

- Stool form (Bristol scale, a seven-point stool-form chart): loose stools mean the osmotic ceiling has been reached.  
- Sleep latency and nocturnal awakenings, if those were the reason for an evening salt.  
- Resting muscle tightness, palpitations, and migraine days, tracked against the person's own baseline.  
- Energy on ordinary training days, without expecting a performance drug effect.  
  

## Emerging Research

- **Glycinate blood-pressure trial:** [NCT05690464](https://clinicaltrials.gov/study/NCT05690464) (Brigham and Women's Hospital; n=120; active, not recruiting) tests 480 mg/day magnesium glycinate for 12 weeks on systolic pressure 130–154 mm Hg. A clear drop would strengthen the blood-pressure case with a well-absorbed salt; a null result would weaken form-agnostic pooling.  
- **Sarcopenia trial:** [NCT07567963](https://clinicaltrials.gov/study/NCT07567963) (SARCOMAG; n=352; not yet recruiting) randomizes older adults with sarcopenia (age-related loss of muscle) and low magnesium to 400 mg/day elemental magnesium citrate versus placebo for 12 weeks. Positive strength results would add a functional endpoint; a null would limit muscle claims.  
- **Vascular calcification already tested:** MAGiCAL-CKD ([NCT02542319](https://clinicaltrials.gov/study/NCT02542319); [Bressendorff et al., 2023](https://pubmed.ncbi.nlm.nih.gov/36749131/)) found no slowing of coronary calcification and more serious events on magnesium hydroxide in advanced kidney disease—evidence against using high-dose magnesium as a calcification drug in that group.  
- **Hospital arrhythmia prophylaxis:** A 2026 analysis in 171,727 intensive-care admissions found no benefit against tachyarrhythmia (abnormally fast heart rhythm) from routine supplementation near usual cutoffs (1.6–2.0 mg/dL), weakening “replace to the reference range to prevent arrhythmia” as a general rule ([Goulden et al., 2026](https://pubmed.ncbi.nlm.nih.gov/41359319/)).  
- **Cognition U-shape:** [Chen et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39009081/) associated both low and high serum magnesium with dementia risk around 0.85 mmol/L. That cautions against “higher serum is better” even if it does not prove oral-supplement harm.  
- **Threonate replication:** [NCT07706283](https://clinicaltrials.gov/study/NCT07706283) (completed, n=81) tested sex-divergent effects of magnesium L-Threonate on sleep, cognition, and neuromuscular function. Independent results matter because earlier cognitive trials were small and industry-linked.  
  

## Conclusion
Oral magnesium is an essential mineral, not a specialty drug, used to close a common intake gap and, in some salts, as a stool-loosening agent. For longevity-oriented adults the strongest trial signal is a small drop in blood pressure, more visible in people who already have high pressure or low magnesium at the start. Blood-sugar handling and a general inflammation marker also move in a favorable direction in pooled trials, again more clearly when baseline status is low. Sleep, mood, bone, migraine, and restless-legs evidence is thinner or mixed, and the popular use for night cramps is not supported in older adults.  

Claims that extra magnesium from supplements lengthens life rest on food-intake studies, not on supplement trials. Extra magnesium from supplements was not tied to lower death rates in the large pooling of cohorts. Gut cramping and loose stools are the usual limiting effects when kidneys work. Dangerously high blood magnesium is mainly a problem when kidneys cannot excrete the load, especially from high-dose laxatives or antacids. Form, timing, and kidney function change both benefit and risk. The evidence base is broad for blood pressure and blood sugar, modest and uneven for brain and sleep claims, and still thin for supplement-driven longevity.  

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**